Limor Zur-Stoller
Keine laufenden Positionen mehr
Profil
Limor Zur-Stoller served as Vice President-Finance & Investor Relations at RadView Software Ltd.
She was also Chief Financial Officer & Treasurer at Gammacan International, Inc. from 2008 to 2011.
From 2008 to 2010, she held the position of Vice President-Finance at Rosetta Genomics Ltd.
Later, she served as Chief Financial Officer & IR Contact at G.F.C Green Fields Capital Ltd.
from 2012 to 2015.
Zur-Stoller completed her undergraduate degree from Tel-Aviv University.
Ehemalige bekannte Positionen von Limor Zur-Stoller
| Unternehmen | Position | Ende |
|---|---|---|
| ROSETTA GENOMICS LTD. | Finanzdirektor/CFO | 01.10.2010 |
| G.F.C GREEN FIELDS CAPITAL LTD. | Finanzdirektor/CFO | - |
Gammacan International, Inc.
 Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | Finanzdirektor/CFO | - |
| RADVIEW SOFTWARE LTD. | Finanzdirektor/CFO | - |
Ausbildung von Limor Zur-Stoller
| Tel-Aviv University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| RADVIEW SOFTWARE LTD. | Technology Services |
| ROSETTA GENOMICS LTD. | Health Technology |
| G.F.C GREEN FIELDS CAPITAL LTD. | Finance |
| Private Unternehmen | 1 |
|---|---|
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | Health Technology |
